nach oben

Annals of Hematology

Erschienen in:

29.10.2020 | Original Article

The role of novel agents for consolidation after autologous transplantation in newly diagnosed multiple myeloma: a systematic review

verfasst von: Nico Gagelmann, Nicolaus Kröger

Erschienen in: Annals of Hematology | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Despite the increasing inclusion of novel agents within the multiple myeloma (MM) treatment sequence, their role for posttransplant consolidation therapy remains unclear. We systematically reviewed studies evaluating the efficacy of novel agent consolidation. We identified 11 citations on 12 prospective comparative studies, and 5 citations were single-arm or comparative studies with preliminary results. Nine different regimens were evaluated in 5905 patients. Risk assessment yielded serious risk of bias and heterogeneity across study designs was high. Irrespective of the regimen, deepened responses after consolidation were seen and improvements were more pronounced with multi-agent consolidation. Bortezomib, thalidomide, and dexamethasone improved long-term survival versus duplet consolidation, including in patients with high-risk cytogenetics. The addition of daratumumab to triplet regimens yielded modestly improved responses with significantly increased rates of minimal residual disease negativity but survival results were limited by short follow-up. In high-risk MM, responses were not different, whereas progression-free survival appeared to be improved with consolidation therapy, challenging the association of response and overall outcome in this subgroup. Our findings highlight the necessity of longer follow-up and consistent reporting to ensure comparability of studies to enable better evidence assessment and to identify patients benefitting from consolidation therapy.

Moreau P, San Miguel J, Sonneveld P et al (2017) Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl_4):iv52–iv61. https://doi.org/10.1093/annonc/mdx096 CrossRefPubMed

Kumar SK, Callander NS, Hillengass J, Liedtke M, Baljevic M, Campagnaro E, Castillo JJ, Chandler JC, Cornell RF, Costello C, Efebera Y, Faiman M, Garfall A, Godby K, Holmberg L, Htut M, Huff CA, Kang Y, Landgren O, Malek E, Martin T, Omel J, Raje N, Sborov D, Singhal S, Stockerl-Goldstein K, Tan C, Weber D, Johnson-Chilla A, Keller J, Kumar R (2019) NCCN Guidelines insights: multiple myeloma, Version 1.2020. J Natl Compr Cancer Netw 17(10):1154–1165. https://doi.org/10.6004/jnccn.2019.0049 CrossRef

Munshi NC, Avet-Loiseau H, Rawstron AC, Owen RG, Child JA, Thakurta A, Sherrington P, Samur MK, Georgieva A, Anderson KC, Gregory WM (2017) Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol 3(1):28–35. https://doi.org/10.1001/jamaoncol.2016.3160 CrossRefPubMedPubMedCentral

Gay F, Jackson G, Rosiñol L, Holstein SA, Moreau P, Spada S, Davies F, Lahuerta JJ, Leleu X, Bringhen S, Evangelista A, Hulin C, Panzani U, Cairns DA, di Raimondo F, Macro M, Liberati AM, Pawlyn C, Offidani M, Spencer A, Hájek R, Terpos E, Morgan GJ, Bladé J, Sonneveld P, San-Miguel J, McCarthy PL, Ludwig H, Boccadoro M, Mateos MV, Attal M (2018) Maintenance treatment and survival in patients with myeloma: a systematic review and network meta-analysis. JAMA Oncol 4(10):1389–1397. https://doi.org/10.1001/jamaoncol.2018.2961 CrossRefPubMedPubMedCentral

McCarthy PL, Holstein SA, Petrucci MT et al (2017) Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol 35(29):3279–3289. https://doi.org/10.1200/JCO.2017.72.6679 CrossRefPubMedPubMedCentral

Mohty M, Richardson PG, McCarthy PL et al (2015) Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand? Bone Marrow Transplant 50(8):1024–1029. https://doi.org/10.1038/bmt.2015.83 CrossRefPubMed

Barlogie B, Tricot G, Rasmussen E, Anaissie E, van Rhee F, Zangari M, Fassas A, Hollmig K, Pineda-Roman M, Shaughnessy J, Epstein J, Crowley J (2006) Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood 107(7):2633–2638. https://doi.org/10.1182/blood-2005-10-4084 CrossRefPubMed

Harousseau J-L, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M, Lenain P, Hulin C, Facon T, Casassus P, Michallet M, Maisonneuve H, Benboubker L, Maloisel F, Petillon MO, Webb I, Mathiot C, Moreau P (2010) Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 28(30):4621–4629. https://doi.org/10.1200/JCO.2009.27.9158 CrossRefPubMed

Al-Ani F, Louzada M (2017) Post-transplant consolidation plus lenalidomide maintenance vs lenalidomide maintenance alone in multiple myeloma: a systematic review. Eur J Haematol 99(6):479–488. https://doi.org/10.1111/ejh.12961 CrossRefPubMed

10.

Zhang S, Kulkarni AA, Xu B, Chu H, Kourelis T, Go RS, Wang ML, Bachanova V, Wang Y (2020) Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis. Blood Cancer J 10(3):33. https://doi.org/10.1038/s41408-020-0298-1 CrossRefPubMedPubMedCentral

11.

Scott K, Hayden PJ, Will A, Wheatley K, Coyne I, Cochrane Haematological Malignancies Group (2016) Bortezomib for the treatment of multiple myeloma. Cochrane Database Syst Rev 4:CD010816. https://doi.org/10.1002/14651858.CD010816.pub2 CrossRefPubMed

12.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700. https://doi.org/10.1136/bmj.b2700 CrossRefPubMedPubMedCentral

13.

Higgins JPT, Altman DG, Gøtzsche PC et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https://doi.org/10.1136/bmj.d5928 CrossRefPubMedPubMedCentral

14.

Mellqvist U-H, Gimsing P, Hjertner O, Lenhoff S, Laane E, Remes K, Steingrimsdottir H, Abildgaard N, Ahlberg L, Blimark C, Dahl IM, Forsberg K, Gedde-Dahl T, Gregersen H, Gruber A, Guldbrandsen N, Haukås E, Carlson K, Kvam AK, Nahi H, Lindås R, Andersen NF, Turesson I, Waage A, Westin J, Nordic Myeloma Study Group (2013) Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood 121(23):4647–4654. https://doi.org/10.1182/blood-2012-11-464503 CrossRefPubMedPubMedCentral

15.

Einsele H, Knop S, Vogel M, Müller J, Kropff M, Metzner B, Langer C, Sayer H, Jung W, Dürk HA, Salwender H, Wandt H, Bassermann F, Gramatzki M, Rösler W, Wolf HH, Brugger W, Engelhardt M, Fischer T, Liebisch P, Straka C (2017) Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma. Leukemia 31(6):1463–1466. https://doi.org/10.1038/leu.2017.83 CrossRefPubMed

16.

Sezer O, Beksac M, Hajek R, Sucak G, Cagirgan S, Linkesch W, Meltem Akay O, Gülbas Z, Nahi H, Plesner T, Snowden JA, Timurağaoğlu A, Dechow T, Lang A, Tuğlular T, Drach J, Armbrecht G, Potamianou A, Couturier C, Olie RA, Feys C, Allietta N, Terpos E (2017) Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study. Br J Haematol 178(1):61–71. https://doi.org/10.1111/bjh.14637 CrossRefPubMed

17.

Kalff A, Kennedy N, Smiley A, Prince HM, Roberts AW, Bradstock K, de Abreu Lourenço R, Frampton C, Spencer A (2014) Thalidomide and prednisolone versus prednisolone alone as consolidation therapy after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the ALLG MM6 multicentre, open-label, randomised phase 3 study. Lancet Haematol 1(3):e112–e119. https://doi.org/10.1016/S2352-3026(14)00022-2 CrossRefPubMed

18.

Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D, Crippa C, Boccadoro M, Perrone G, Falcone A, Nozzoli C, Zambello R, Masini L, Furlan A, Brioli A, Derudas D, Ballanti S, Dessanti ML, de Stefano V, Carella AM, Marcatti M, Nozza A, Ferrara F, Callea V, Califano C, Pezzi A, Baraldi A, Grasso M, Musto P, Palumbo A (2012) Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 120(1):9–19. https://doi.org/10.1182/blood-2012-02-408898 CrossRefPubMed

19.

Leleu X, Fouquet G, Hebraud B et al (2013) Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma. Leukemia 27(11):2242–2244. https://doi.org/10.1038/leu.2013.101 CrossRefPubMed

20.

Horvath N, Spencer A, Kenealy M, Joshua D, Campbell PJ, Lee JJ, Hou J, Qiu L, Kalff A, Khong T, Londhe A, Siggins S, van Kooten Losio M, Eisbacher M, Prince HM (2019) Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study. Leuk Lymphoma 60(9):2122–2133. https://doi.org/10.1080/10428194.2019.1579322 CrossRefPubMed

21.

Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Horowitz MM, Koreth J, Knust K, Landau H, Brunstein C, McCarthy P, Nelson C, Qazilbash MH, Shah N, Vesole DH, Vij R, Vogl DT, Giralt S, Somlo G, Krishnan A (2019) Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial. J Clin Oncol 37(7):589–597. https://doi.org/10.1200/JCO.18.00685 CrossRefPubMedPubMedCentral

22.

Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, Dozza L, van der Holt B, Zweegman S, Oliva S, van der Velden VHJ, Zamagni E, Palumbo GA, Patriarca F, Montefusco V, Galli M, Maisnar V, Gamberi B, Hansson M, Belotti A, Pour L, Ypma P, Grasso M, Croockewit A, Ballanti S, Offidani M, Vincelli ID, Zambello R, Liberati AM, Andersen NF, Broijl A, Troia R, Pascarella A, Benevolo G, Levin MD, Bos G, Ludwig H, Aquino S, Morelli AM, Wu KL, Boersma R, Hajek R, Durian M, von dem Borne PA, Caravita di Toritto T, Zander T, Driessen C, Specchia G, Waage A, Gimsing P, Mellqvist UH, van Marwijk Kooy M, Minnema M, Mandigers C, Cafro AM, Palmas A, Carvalho S, Spencer A, Boccadoro M, Sonneveld P (2020) Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol 7(6):e456–e468. https://doi.org/10.1016/S2352-3026(20)30099-5 CrossRefPubMed

23.

Wester R, van der Holt B, Asselbergs E, Zweegman S, Kersten MJ, Vellenga E, van Marwijk Kooy M, de Weerdt O, Minnema M, Lonergan S, Palumbo A, Lokhorst H, Broijl A, Sonneveld P (2019) Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial. Haematologica 104(11):2265–2273. https://doi.org/10.3324/haematol.2018.205476 CrossRefPubMedPubMedCentral

24.

Gay F, Cerrato C, Scalabrini DR et al (2018) Carfilzomib-lenalidomide-dexamethasone (KRd) induction-autologous transplant (ASCT)-Krd consolidation vs KRd 12 cycles vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction-ASCT-KCd consolidation: analysis of the randomized forte trial in newly diagnosed multiple myeloma (NDMM). Blood 132(Supplement 1):121CrossRef

25.

Vij R, Nathwani N, Martin TG et al (2018) Ixazomib-lenalidomide-dexamethasone (IRd) consolidation following autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a large multi-center phase II trial. Blood 132(Supplement 1):123CrossRef

26.

Roussel M, Hebraud B, Hulin C et al (2019) Twice weekly induction with ixazomib-lenalidomide-dexamethasone (IRd) combination followed by extended IRD consolidation and lenalidomide maintenance in transplant eligible patients with newly diagnosed multiple myeloma (NDMM): a phase 2 study from the Intergroupe Francophone Du Myelome (IFM 2014-03). Blood 134(Supplement_1):3159CrossRef

27.

Paiva B, Puig N, Cedena M-T, Rosiñol L, Cordón L, Vidriales MB, Burgos L, Flores-Montero J, Sanoja-Flores L, Lopez-Anglada L, Maldonado R, de la Cruz J, Gutierrez NC, Calasanz MJ, Martin-Ramos ML, Garcia-Sanz R, Martinez-Lopez J, Oriol A, Blanchard MJ, Rios R, Martin J, Martinez-Martinez R, Sureda A, Hernandez MT, de la Rubia J, Krsnik I, Moraleda JM, Palomera L, Bargay J, van Dongen JJM, Orfao A, Mateos MV, Blade J, San-Miguel JF, Lahuerta JJ, on behalf of the GEM (Grupo Español de Mieloma)/PETHEMA (Programa Para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group (2020) Measurable residual disease by next-generation flow cytometry in multiple myeloma. J Clin Oncol 38(8):784–792. https://doi.org/10.1200/JCO.19.01231 CrossRefPubMed

28.

Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, Béné MC, Broijl A, Caillon H, Caillot D, Corre J, Delforge M, Dejoie T, Doyen C, Facon T, Sonntag C, Fontan J, Garderet L, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Lenain P, Macro M, Mathiot C, Orsini-Piocelle F, Perrot A, Stoppa AM, van de Donk NWCJ, Wuilleme S, Zweegman S, Kolb B, Touzeau C, Roussel M, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Fermand JP, Escoffre-Barbe M, Eveillard JR, Garidi R, Ahmadi T, Zhuang S, Chiu C, Pei L, de Boer C, Smith E, Deraedt W, Kampfenkel T, Schecter J, Vermeulen J, Avet-Loiseau H, Sonneveld P (2019) Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet 394(10192):29–38. https://doi.org/10.1016/S0140-6736(19)31240-1 CrossRefPubMed

29.

Voorhees PM, Kaufman JL, Laubach JP, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD Jr, Nathwani N, Shah N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Murphy S, Lutska Y, Pei H, Ukropec J, Vermeulen J, de Boer C, Hoehn D, Lin TS, Richardson PG (2020) Daratumumab, lenalidomide, bortezomib, & dexamethasone for transplant-eligible newly diagnosed multiple myeloma: GRIFFIN. Blood 136:936–945. https://doi.org/10.1182/blood.2020005288 CrossRefPubMedPubMedCentral

30.

Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, Montori V, Akl EA, Djulbegovic B, Falck-Ytter Y (2011) GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). J Clin Epidemiol 64(4):407–415. https://doi.org/10.1016/j.jclinepi.2010.07.017 CrossRefPubMed

31.

San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359(9):906–917. https://doi.org/10.1056/NEJMoa0801479 CrossRefPubMed

32.

Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, Thakuri M, Reu F, Reynolds CM, Sexton R, Orlowski RZ, Barlogie B, Dispenzieri A (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389(10068):519–527. https://doi.org/10.1016/S0140-6736(16)31594-X CrossRefPubMed

33.

Straka C, Knop S, Vogel M, Müller J, Kropff M, Metzner B, Langer C, Sayer H, Jung W, Dürk HA, Salwender H, Wandt H, Bassermann F, Gramatzki M, Rösler W, Wolf HH, Brugger W, Fischer T, Liebisch P, Engelhardt M, Einsele H (2019) Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials. Eur J Haematol 103(3):255–267. https://doi.org/10.1111/ejh.13281 CrossRefPubMed

34.

Spencer A, Prince HM, Roberts AW, Prosser IW, Bradstock KF, Coyle L, Gill DS, Horvath N, Reynolds J, Kennedy N (2009) Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 27(11):1788–1793. https://doi.org/10.1200/JCO.2008.18.8573 CrossRefPubMed

35.

Tacchetti P, Patriarca F, Petrucci MT et al (2018) A triplet bortezomib- and immunomodulator-based therapy before and after double ASCT improves overall survival in newly diagnosed MM patients: final analysis of phase 3 GIMEMA-MMY-3006 study. Hemasphere 2(S1):S105

36.

Landgren O, Sonneveld P, Jakubowiak A, Mohty M, Iskander KS, Mezzi K, Siegel DS (2019) Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma. Leukemia 33(9):2127–2143. https://doi.org/10.1038/s41375-019-0517-6 CrossRefPubMedPubMedCentral

37.

Alanazi F, Kwa FAA, Burchall G, Jackson DE (2020) New generation drugs for treatment of multiple myeloma. Drug Discov Today 25(2):367–379. https://doi.org/10.1016/j.drudis.2019.11.008 CrossRefPubMed

38.

Goldschmidt H, Dimopoulos MA, Rajkumar SV, Weisel KC, Moreau P, Chng WJ, Mikala G, Cavo M, Ramasamy K, Suryanarayan K, Teng Z, Labotka R, Mateos MV (2020) Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma. Leukemia 34:3019–3027. https://doi.org/10.1038/s41375-020-0819-8 CrossRefPubMedPubMedCentral

39.

Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, di Bacco A, Hui AM, van de Velde H, Richardson PG, TOURMALINE-MM1 Study Group (2016) Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374(17):1621–1634. https://doi.org/10.1056/NEJMoa1516282 CrossRefPubMed

40.

Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, Minnema MC, Lassen U, Krejcik J, Palumbo A, van de Donk NWCJ, Ahmadi T, Khan I, Uhlar CM, Wang J, Sasser AK, Losic N, Lisby S, Basse L, Brun N, Richardson PG (2015) Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 373(13):1207–1219. https://doi.org/10.1056/NEJMoa1506348 CrossRefPubMed

41.

Abdallah N, Kumar SK (2019) Daratumumab in untreated newly diagnosed multiple myeloma. Ther Adv Hematol 10:2040620719894871. https://doi.org/10.1177/2040620719894871 CrossRefPubMedPubMedCentral

42.

Sonneveld P, Beksac M, vander Holt B et al (2018) Consolidation followed by maintenance vs maintenance alone in newly diagnosed, transplant eligible multiple myeloma: a randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM TRIAL). Hemasphere 2(S1):S108

43.

Hari P, Pasquini MC, Stadtmauer EA et al (2020) Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM). J Clin Oncol 38(suppl):abstr 8506CrossRef

44.

Nooka AK, Kaufman JL, Muppidi S, Langston A, Heffner LT, Gleason C, Casbourne D, Saxe D, Boise LH, Lonial S (2014) Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia 28(3):690–693. https://doi.org/10.1038/leu.2013.335 CrossRefPubMed

45.

Touzeau C, Moreau P, Perrot A et al (2020) Daratumumab + bortezomib, thalidomide, and dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM): baseline SLiM-CRAB based subgroup analysis of CASSIOPEIA. J Clin Oncol 38(suppl):abstr 8538CrossRef

46.

Luo J, Gagne JJ, Landon J, Avorn J, Kesselheim AS (2017) Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: a population-based cohort study. Eur J Cancer 70:22–33. https://doi.org/10.1016/j.ejca.2016.10.018 CrossRefPubMed

47.

Engelhardt M, Domm A-S, Dold SM, Ihorst G, Reinhardt H, Zober A, Hieke S, Baayen C, Müller SJ, Einsele H, Sonneveld P, Landgren O, Schumacher M, Wäsch R (2017) A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica 102(5):910–921. https://doi.org/10.3324/haematol.2016.162693 CrossRefPubMedPubMedCentral

48.

Larocca A, Dold SM, Zweegman S, Terpos E, Wäsch R, D’Agostino M, Scheubeck S, Goldschmidt H, Gay F, Cavo M, Ludwig H, Straka C, Bringhen S, Auner HW, Caers J, Gramatzki M, Offidani M, Dimopoulos MA, Einsele H, Boccadoro M, Sonneveld P, Engelhardt M (2018) Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). Leukemia 32(8):1697–1712. https://doi.org/10.1038/s41375-018-0142-9 CrossRefPubMed

49.

Saad A, Mahindra A, Zhang M-J et al (2014) Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant 20(3):402–408.e1. https://doi.org/10.1016/j.bbmt.2013.12.557 CrossRefPubMed

Titel: The role of novel agents for consolidation after autologous transplantation in newly diagnosed multiple myeloma: a systematic review
verfasst von: Nico Gagelmann
Nicolaus Kröger
Publikationsdatum: 29.10.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Annals of Hematology / Ausgabe 2/2021
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-020-04316-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The role of novel agents for consolidation after autologous transplantation in newly diagnosed multiple myeloma: a systematic review

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

Krüppel-like factor 1 (KLF1) gene single nucleotide polymorphisms in sickle cell disease and its association with disease-related morbidities

Primary pulmonary diffuse large B cell lymphoma presenting as bulky bilateral lung tumors

COVID-19 in cancer patients: clinical characteristics and outcome—an analysis of the LEOSS registry

Preemptive low-dose interleukin-2 or DLI for late-onset minimal residual disease in acute leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation

Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA)

Durable remission with ruxolitinib in a chronic neutrophilic leukemia patient harboring a truncation and membrane proximal CSF3R compound mutation

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin